[ad_1]
In the spring of 2020, many pharmaceutical companies faced supply chain disruptions as the Covid-19 pandemic spread. The chemicals used to make key pharmaceutical ingredients are often sourced from only a handful of suppliers in China—sometimes from just one.
The pandemic has revealed how reliant the global pharmaceutical supply chain is on China, even for the most basic ingredients.
This is the final installment in a series of articles by Nikkei Asia about Beijing’s goal of becoming the center of the global pharmaceutical industry. This issue focuses on China’s market dominance of active pharmaceutical ingredients – a dominance that is being challenged by some Western countries as Covid-19 and geopolitical tensions expose supply chain vulnerabilities.
read more here.
a version of this article First published by Nikkei Asia, April 5, 2022. ©2022 Nikkei Inc. All Rights Reserved
Related Stories
This article comes from Nikkei Asia, a global publication that looks at politics, economics, business and international affairs from a unique Asian perspective. Our own correspondents and external commentators from around the world share their perspectives on Asia, while our Asia300 section provides in-depth coverage of the 300 largest and fastest-growing listed companies from 11 economies outside Japan.
[ad_2]
Source link
